Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

CECLOR(END ITALICS) LOTS DISTRIBUTED BY QUALITY KING BEING RECALLED "because some ]of the capsules[ may be counterfeit or unauthorized foreignmade versions of the drug," FDA announced in a Sept. 27 "Talk Paper." The agency noted that the Quality King supplies of Lilly's Ceclor (cefaclor) went to nine retailers and whslrs: Eagel Drug Inc. Rx of Eden Prairie, Minn.; Giant Rx Distributors of Baltimore, Md.; K&B Rx of Metairie, La.; H.L. Moore Co. Rx of New Britain, Conn.; Northwestern Drug of Auburn, Wash.; Revco of Dallas, Texas; Revco of Knoxville, Tenn.; Snyder Drug Warehouse of Eagen, Minn., and Mark Stevens Rx of Woonsocket, R.I. FDA said "at least two of the Quality King-distributed lots have a different appearance and different lot numbers from those used by Lilly." The lot numbers for the recalled products are 9BQ56A for the 250 mg capsules and 8TSl2B for the 500 mg capsules. FDA noted that the alleged counterfeit Ceclor is also identifiable by the capsule shape (Quality King-distributed products have a hemispheric shape while Lilly's are bullet-shaped); the absence of the product name and dosage strength on the capsule; and by the expiration date, the month of which is fully spelled out on the counterfeit label and abbreviated on the authentic Lilly label. FDA also noted that eight other Lilly lots distributed by Quality King are being recalled by the distributor because "their source and condition of storage are not certain." These lot numbers are: 8EW84B, 8FA25B, 7PC88A, 8EG63A in the 250 mg strength, and 8ED12A, 8DB43A, 7SS14A, 7PG44A in the 500 mg strength. The agency explained that "other Ceclor packages may bear these eight lot numbers but are NOT suspect and NOT being recalled IF their source was a regular Lilly distributor or any other distributor but Quality King and their sub-distributors." Quality King began recalling the Ceclor products Sept. 23. On Sept. 26, Lilly filed suit against the firm in the federal court of New York for trademark infringement and unfair competition. The court issued a same-day temporary restraining order that bars Quality King from distributing products with Lilly's Ceclor trademark. Lilly's suit states that Quality King and its President Bernard Nussdorf imported and sold to U.S. retail pharmacies "certain quantities of cefaclor antibiotic, which is prominently identified by ]Lilly's[ trademarks Ceclor and LlLLY, which imitates the labeling used by ]Lilly[ on the Ceclor product sold in the U.S., and which otherwise represents that ]Lilly[ is the source of the drug product so labeled and packaged whereas in fact said product has been rebottled and repacked by some entity other than ]Lilly[ or any company authorized by ]Lilly[." Lilly's complaint is the second suit filed against Deer Park, NY-based Quality King in the past month. The whslr. was named with the Polish government company DAL Internatl. in a suit brought by J&J over the diversion of J&J's Reach toothbrushes and baby products ("The Pink Sheet" Sept. 16, T&G-9). J&J claimed that DAL fraudulently purchased the J&J products by representing that it intended to sell the products solely in Poland and in fact distributed them in the U.S. via Quality King. In issuing a preliminary injunction to restrain movement of the J&J goods, Newark Federal Judge Dickinson Debevoise stated that "while the evidence does not show that Quality King participated in the fraud, it cannot be held to be a bonafide purchaser."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts